2. Immunology/Inflammation
  3. CD28

CD28

CD28, a cell surface glycoprotein receptor, predominantly expressed on activated T cells, belongs to the Ig superfamily and provides a critical co-stimulatory signal. Its ligands, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4. CD28 interacts with the CD80 dimer with relatively high affinity and the CD86 monomer with lower affinity, mediating T cell co-stimulation in conjunction with T cell receptor (TCR) signals. CD28 drives critical intracellular biochemical events including unique phosphorylation and transcriptional signaling, metabolism, and the production of key cytokines, chemokines, and survival signals that are essential for long-term expansion and differentiation of T cells. Most importantly, treatment of mice with a soluble CD28 antagonist induced antigen-specific tolerance that prevented the progression of autoimmune diseases and organ graft rejection.

CD28 Related Products (32):

Cat. No. Product Name Effect Purity
  • HY-P9986
    Tiragolumab Inhibitor
    Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma[1][2][3][4].
  • HY-P99123
    Anti-Mouse CD28 Antibody (37.51)
    Anti-Mouse CD28 Antibody is an anti-mouse CD28 IgG antibody inhibitor derived from the host Syrian Hamster.
  • HY-P99302
    Lulizumab Inhibitor
    Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft[1][2].
  • HY-P9975
    Theralizumab Agonist 99.46%
    Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis[1][2].
  • HY-P99961
    Tifcemalimab Inhibitor
    Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer[1].
  • HY-176265
    DDS5 Inhibitor
    DDS5 is a CD28 inhibitor with a kd of 175.57 µM. DDS5 significantly inhibits CD28-CD80 interaction (IC50: 332 µM). DDS5 can be used for research of immune-mediated diseases, including inflammatory bowel disease and rheumatoid arthritis[1].
  • HY-P991176
    RG-6333 Agonist
    RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003)[1][2].
  • HY-19486
    UR-1505 Inhibitor
    UR-1505 is a nuclear factor of activated T cells (NF-AT) inhibitor. UR-1505 can suppress CD3/CD28 induced T cell proliferation, increase p27KIP levels, and induce G1/S cell cycle arrest. UR-1505 can also inhibit the production of IL-5 and IFN-γ in activated T cells. UR-1505 has immunomodulatory properties and can be used in the study of atopic dermatitis[1].
  • HY-P990236
    Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A)
    Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse/rat/monkey/human ICOS/CD278.
  • HY-P990803
    Anti-Mouse CD28 Antibody (PV-1) Inhibitor
    Anti-Mouse CD28 Antibody (PV-1) is a kind of Armenian hamster IgG in vivo mouse antibody, targeting to CD28. The recommend isotype control of Anti-Mouse CD28 Antibody (PV-1): Armenian hamster IgG, Isotype Control (HY-P990305).
  • HY-P991038
    Zadoprubart 99%
    HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)[1].
  • HY-P990819
    Anti-Rat CD28 Antibody (JJ316) Inhibitor
    Anti-Rat CD28 Antibody (JJ316) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to CD28. The recommend isotype control of Anti-Rat CD28 Antibody (JJ316): Mouse IgG1 kappa, Isotype Control (HY-P99977).
  • HY-P99431
    KY-1044 99.51%
    KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response[1].
  • HY-P990752
    Nezastomig
    Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody[1]. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
  • HY-P990793
    Anti-Mouse CD28 Antibody (D665) Inhibitor
    Anti-Mouse CD28 Antibody (D665) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to CD28. The recommend isotype control of Anti-Mouse CD28 Antibody (D665): Mouse IgG1 kappa, Isotype Control (HY-P99977).
  • HY-169819
    Calcium influx inducer compound 634 Activator
    Calcium influx inducer compound 634 is a calcium influx inducer. Calcium influx inducer compound 634 (10 µM) enhances the release of extracellular vesicles (EVs) from mouse bone marrow-derived dendritic cells (mBMDCs). Calcium influx inducer compound 634 (10 µM) also increases the levels of CD86 and CD80 on the surface of mBMDCs, an effect that can be blocked by the calcium release-activated calcium channel inhibitor YM-58483 (HY-100831)[1].
  • HY-N10445
    Maydispenoid A
    Maydispenoid A is a potent immunosuppressor. Maydispenoid A can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation[1].
  • HY-P99420
    Acazicolcept Antagonist 99.27%
    Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities[1].
  • HY-P99293
    Galiximab Inhibitor
    Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors[1][2].
  • HY-P1698
    Reltecimod Antagonist 99.88%
    Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs)[1][2].